New autoinjector technology for the delivery of subcutaneous methotrexate in the treatment of rheumatoid arthritis

Expert Review of Medical Devices

Volumn 11, Issue 5, 2014, Pages 447-455

  Schiff, Michael ^a   Jaffe, Jonathan ^b   Freundlich, Bruce ^b,c   Madsen, Patrick ^d  

^a UNIVERSITY OF COLORADO   (United States)

^b Clinical Development Antares Pharma Inc   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Antares Pharma Inc   (United States)

Author keywords

auto injector; disease modifying antirheumatic drug; Otrexup; pre filled syringe; rheumatoid arthritis; self administration; subcutaneous methotrexate

Indexed keywords

AUTO-INJECTOR; DISEASE-MODIFYING ANTIRHEUMATIC DRUG; OTREXUP; PRE-FILLED SYRINGE; RHEUMATOID ARTHRITIS; SELF-ADMINISTRATION; SUBCUTANEOUS METHOTREXATE;

DISEASES;

ANTIRHEUMATIC AGENT; METHOTREXATE;

ARTHRITIS, RHEUMATOID; DEVICES; DRUG DELIVERY SYSTEM; HUMAN; PROCEDURES; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG DELIVERY SYSTEMS; HUMANS; INJECTIONS, SUBCUTANEOUS; METHOTREXATE;

EID: 84905860091     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/17434440.2014.929492     Document Type: Article

References (40)

1. Dunkin MA. Who gets RA? In: Arthritis Foundation. 2014. Available from: www. arthritistoday.org/about-arthritis/types-ofarthritis/rheumatoid-arthritis/ who-gets-raand-why/who-gets-ra/how-do-you-get-ra.php
2. Lipsky P. Rheumatoid arthritis. In: Longo DL, Kasper DL, Jameson JL, et al. editors. Harrison's principles of internal medicine. McGraw-Hill; New York, NY, USA: 2008
3. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64(5):625-39
4. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73(3):492-509
5. Fleischmann R. Don't forget traditional DMARDs. Rheumatology (Oxford) 2011; 50(3):429-30
6. Sokka T, Kautiainen H, Toloza S, et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis 2007;66(11):1491-6
7. Yazici Y, Sokka T, Kautiainen H, et al. Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 2005;64(2):207-11
8. Schiff M, Jaffe J, Freundlich B. Head-tohead, randomized, crossover study of oral vs subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses 15 mg may be overcome with subcutaneous administration. Ann Rheum Dis 2014. [Epub ahead of print]
9. Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004;31(4):645-8
10. Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007;65(3):168-73
11. Rutkowska-Sak L, Rell-Bakalarska M, Lisowska B. Oral vs. subcutaneous low-dose methotrexate treatment in reducing gastrointestinal side effects. Reumatologia 2009;47(4):207-11
12. Jacobs JW. Lessons for the use of non-biologic anchor treatments for rheumatoid arthritis in the era of biologic therapies. Rheumatology (Oxford) 2012; 51(Suppl 4):iv27-33
13. Braun J, Kastner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008;58(1):73-81
14. Bakker MF, Jacobs JW, Welsing PM, et al. Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. Ann Rheum Dis 2010;69(10):1849-52
15. Mainman H, McClaren E, Heycock C, et al. When should we use parenteral methotrexate? Clin Rheumatol 2010;29(10): 1093-8
16. Wegrzyn J, Adeleine P, Miossec P. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis 2004;63(10):1232-4
17. Brorsson S, Nilsdotter A, Pedersen E, et al. Relationship between finger flexion and extension force in healthy women and women with rheumatoid arthritis. J Rehabil Med 2012;44(7):605-8
18. Whalley D, McKenna SP, de Jong Z, van der Heijde D. Quality of life in rheumatoid arthritis. Br J Rheumatol 1997; 36(8):884-8
19. Methotrexate shortage. Update: date of availability. Spondylitis Association of America; CA, USA: 2004
20. Harris G. Supply of a cancer drug may run out within weeks. In: The New York Times. New York, NY, USA: 2012
21. Occupational safety and health administration technical manual. Controlling occupational exposure to hazardous drugs. 1999
22. Enbrel [package insert]. Amgen, Thousand Oaks, CA, USA. 2013
23. Simponi [package insert]. Janssen Biotech, Inc., Horsham, PA, USA. 2013
24. D'Arcy C, Thomas D, Stoneman D, Parkes L. Patient assessment of an electronic device for subcutaneous self-injection of interferon beta-1a for multiple sclerosis: an observational study in the UK and Ireland. Patient Prefer Adherence 2012;6: 55-61
25. Frew AJ. What are the 'ideal' features of an adrenaline (epinephrine) auto-injector in the treatment of anaphylaxis? Allergy 2011; 66(1):15-24
26. Thompson I, Lange J. Pen and autoinjector drug delivery devices. In: Kolhe P, Shah M, Rathore N, Sterile product development. Springer; New York, NY, USA: 2013. p. 331-56
27. Humira [package insert]. AbbVie Inc., North Chicago, IL, USA. 2013
28. Berteau C, Schwarzenbach F, Donazzolo Y, et al. Evaluation of performance, safety, subject acceptance, and compliance of a disposable autoinjector for subcutaneous injections in healthy volunteers. Patient Prefer Adherence 2010;4:379-88
29. Kivitz A, Cohen S, Dowd JE, et al. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. Clin Ther 2006;28(10): 1619-29
30. Pozzilli C, Schweikert B, Ecari U, Oentrich W. BetaPlus Study group. Supportive strategies to improve adherence to IFN beta-1b in multiple sclerosis-results of the betaPlus observational cohort study. J Neurol Sci 2011;307(1-2):120-6
31. TJet [user manual]. Teva Pharmaceuticals; North Wales, PA, USA. 2013
32. Otrexup [package insert]. Antares Pharma, Ewing, NJ, USA. 2013
33. Freundlich B, Kivitz A, Jaffe J. Nearly pain-free self-administration of subcutaneous methotrexate with an auto-injector: results of a phase 2 clinical trial in patients with rheumatoid arthritis who have functional limitations. J Clin Rheumatol In press? A Phase II clinical trial demonstrating the ease of use and minimal pain associated with the MTX autoinjector
34. Kineret [package insert]. Swedish Orphan Biovitrum, Stockholm, Sweden. 2012; In press
35. Cimzia [package insert]. UCB Inc., Smyrna, GA, USA. 2013
36. Orencia [package insert]. Bristol-Myers Squibb Company, Princeton, NJ, USA. 2013
37. Actemra [package insert]. Genentech, Inc., South San Francisco, CA, USA. 2013
38. Fautrel B. Economic benefits of optimizing anchor therapy for rheumatoid arthritis. Rheumatology (Oxford) 2012;51(Suppl 4): iv21-6
39. Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford) 2012; 51(Suppl 5):v38-47
40. Enbrel [instructions for use]. Amgen, Thousand Oaks, CA, USA. 2013